PriceTargets.com logo

Notable Labs - NTBL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 729.02%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.97 As of 04/26/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for NTBL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Notable Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NTBL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NTBL

Analyst Price Target is $8.00
▲ +729.02% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Notable Labs in the last 3 months. The average price target is $8.00, with a high forecast of $9.00 and a low forecast of $7.00. The average price target represents a 729.02% upside from the last price of $0.97.

This chart shows the closing price for NTBL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Notable Labs. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/15/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$9.00Low
4/15/2024Chardan CapitalLower TargetBuy ➝ Buy$9.00 ➝ $7.00Low
12/19/2023JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$13.00 ➝ $9.00Low
11/20/2023Chardan CapitalReiterated RatingBuyLow
10/18/2023JMP SecuritiesInitiated CoverageMarket Outperform$13.00Low
(Data available from 4/27/2019 forward)

News Sentiment Rating

-0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/29/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
12/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/27/2024

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Notable Labs logo
Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.
Read More

Today's Range

Now: $0.97
Low: $0.95
High: $1.07

50 Day Range

MA: $1.41
Low: $0.95
High: $1.91

52 Week Range

Now: $0.97
Low: $0.83
High: $11.20

Volume

143,443 shs

Average Volume

58,669 shs

Market Capitalization

$2.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Notable Labs?

The following Wall Street analysts have issued research reports on Notable Labs in the last twelve months: Chardan Capital, and JMP Securities.
View the latest analyst ratings for NTBL.

What is the current price target for Notable Labs?

2 Wall Street analysts have set twelve-month price targets for Notable Labs in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 729.0%. JMP Securities has the highest price target set, predicting NTBL will reach $9.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $7.00 for Notable Labs in the next year.
View the latest price targets for NTBL.

What is the current consensus analyst rating for Notable Labs?

Notable Labs currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NTBL will outperform the market and that investors should add to their positions of Notable Labs.
View the latest ratings for NTBL.

What other companies compete with Notable Labs?

Other companies that are similar to Notable Labs include Salarius Pharmaceuticals, CNS Pharmaceuticals, Dermata Therapeutics, Clearmind Medicine and Cyclacel Pharmaceuticals. Learn More about companies similar to Notable Labs.

How do I contact Notable Labs' investor relations team?

Notable Labs' physical mailing address is 8 HASATAT STREET, MODI`IN L3, 7178106. The company's listed phone number is (728) 993-5000 and its investor relations email address is [email protected]. The official website for Notable Labs is www.vblrx.com. Learn More about contacing Notable Labs investor relations.